On April 21, 2020 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, reported that the company will present data from its first in human study of PEN-866 at the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting, occurring April 27-28, 2020 (Press release, Tarveda Therapeutics, APR 21, 2020, View Source [SID1234556471]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PEN-866 is the initial clinical program from Tarveda’s HSP90 binding miniature drug conjugate platform, which is designed to bind to activated Heat Shock Protein 90 (HSP90) to accumulate and release its potent topoisomerase 1 inhibitor (SN-38) payload in solid tumors.

Details of the poster presentation are as follows:

Title: Characterization of PEN-866, a Heat Shock Protein 90 (HSP90) binding conjugate of SN-38, in patient plasma and tumors from the first in human study
Date: Monday, April 27, 2020
Time: 9:00 AM – 6:00 PM ET
Location: AACR (Free AACR Whitepaper) Virtual Annual Meeting I accessible on the AACR (Free AACR Whitepaper) website at www.aacr.org